Bori Pharmaceutical releases positive Phase II data for the dual-target receptor agonist BGM0504.

It was learned from BORUI Pharmaceutical that at the 85th Scientific Session of the American Diabetes Association, the company announced the results of two Phase II clinical studies of its independently developed dual-target agonist BGM0504 for glucagon-like peptide-1 receptor/glucose-dependent insulinotropic peptide receptor. Two independent Phase II studies of BGM0504 showed good glycemic efficacy in patients with type 2 diabetes, with preliminary evidence of better clinical efficacy than semaglutide; at the same time, in overweight/obese non-type 2 diabetes adult population, it showed significant potential for weight management and comprehensive benefits in metabolic risk indicators.